Pfizer has long been a leader in pushing the boundaries of science and innovation, and now, AI is redefining how the company approaches drug discovery and development. From accelerating research timelines to uncovering new insights that were once buried in mountains of data, AI, particularly generative AI (GenAI), is transforming the way scientists and researchers work.

But what does this shift look like in practice? How is AI being integrated into the complex world of pharmaceutical R&D, and what challenges still stand in the way?

Jeremy Forman, Vice President of Research & Development AI, Data, & Analytics at Pfizer, explores these questions in conversation with Kevin Barboza, Partner at EY.